AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3, PDGFR alpha/beta and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition, IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%), VEGFR2 (80%), VEGFR3 (67%), PDGFR alpha (82%) and PDGFR beta (82%) expression, whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFR alpha revealed a predominantly cytoplasmatic staining in tumor cells, accompanied by an additional nuclear staining for VEGFR3, EGFR1 was almost exclusively detected on the membrane of tumor cells. PDGFR beta was restricted to stromal pericytes, which also depicted a PDGFR alpha expression. CONCLUSION: Our results reveal a high rate of receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy.
AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in humangastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3, PDGFR alpha/beta and EGFR1 was analyzed by RT-PCR in 51 humangastric adenocarcinomas. In addition, IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%), VEGFR2 (80%), VEGFR3 (67%), PDGFR alpha (82%) and PDGFR beta (82%) expression, whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFR alpha revealed a predominantly cytoplasmatic staining in tumor cells, accompanied by an additional nuclear staining for VEGFR3, EGFR1 was almost exclusively detected on the membrane of tumor cells. PDGFR beta was restricted to stromal pericytes, which also depicted a PDGFR alpha expression. CONCLUSION: Our results reveal a high rate of receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy.
Authors: A Tokunaga; M Onda; T Okuda; T Teramoto; I Fujita; T Mizutani; T Kiyama; T Yoshiyuki; K Nishi; N Matsukura Journal: Cancer Date: 1995-03-15 Impact factor: 6.860
Authors: C Gómez-Martín; R Salazar; C Montagut; M Gil-Martín; J A Núñez; M Puig; X Lin; R Khosravan; J M Tursi; M J Lechuga; J Bellmunt Journal: Invest New Drugs Date: 2012-05-22 Impact factor: 3.850
Authors: Carl C Schimanski; Friederike Schlaegel; Mareike Jordan; Markus Moehler; George Sgourakis; Daniel G Drescher; Peter R Galle; Hauke Lang; Ines Gockel Journal: World J Surg Date: 2011-05 Impact factor: 3.352
Authors: K-W Lee; S R Park; D-Y Oh; Y-I Park; R Khosravan; X Lin; S-Y Lee; E-J Roh; O Valota; M J Lechuga; Y-J Bang Journal: Invest New Drugs Date: 2013-10-04 Impact factor: 3.850
Authors: Carl C Schimanski; Tim Zimmermann; Irene Schmidtmann; Ines Gockel; Hauke Lang; Peter R Galle; Markus Moehler; Martin R Berger Journal: Int J Colorectal Dis Date: 2009-11-20 Impact factor: 2.571
Authors: Jennifer M Davis; Elizabeth Hyjek; Aliya N Husain; Le Shen; Jennifer Jones; Lucia A Schuger Journal: J Histochem Cytochem Date: 2013-04-22 Impact factor: 2.479